Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced...

by Massimo Cristofanilli, Nadia Harbeck, Hope S. Rugo, Aurelio Castrellon, Anil Abraham Joy, Sunil Verma, Seock-Ah Im, Shrividya Iyer, Kathy Puyana Theall, Eric Gauthier, Xin Huang, Cynthia Huang Bartlett, Sibylle Loibl, Richard S. Finn
Published 2020-02-01